Quick Answer
NORTHWEST BIOTHERAPEUTICS INC reported Diluted EPS of $0.07 per share (loss) for fiscal year 2024.
NORTHWEST BIOTHERAPEUTICS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.07 | -16.7% |
| 2023 | -$0.06 | +40.0% |
| 2022 | -$0.10 | -66.7% |
| 2021 | -$0.06 | +91.8% |
| 2020 | -$0.73 | -1725.0% |
| 2019 | -$0.04 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.02 | +0.0% | -100.0% |
| June 30, 2025 | -$0.01 | +50.0% | +0.0% |
| March 31, 2025 | -$0.01 | +50.0% | +50.0% |
| September 30, 2024 | -$0.02 | +0.0% | +0.0% |
| June 30, 2024 | -$0.02 | -100.0% | +0.0% |
| March 31, 2024 | -$0.02 | -100.0% | +0.0% |
| September 30, 2023 | -$0.02 | +33.3% | -100.0% |
| June 30, 2023 | -$0.01 | +0.0% | +0.0% |
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -16.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2024 period, NORTHWEST BIOTHERAPEUTICS INC’s diluted eps has declined by 75.0% (from $0.04 per share (loss) to $0.07 per share (loss)).
- The most recent figure is from NORTHWEST BIOTHERAPEUTICS INC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: